[go: up one dir, main page]

WO2013035737A1 - Nouveau bifidobacterium et son utilisation - Google Patents

Nouveau bifidobacterium et son utilisation Download PDF

Info

Publication number
WO2013035737A1
WO2013035737A1 PCT/JP2012/072605 JP2012072605W WO2013035737A1 WO 2013035737 A1 WO2013035737 A1 WO 2013035737A1 JP 2012072605 W JP2012072605 W JP 2012072605W WO 2013035737 A1 WO2013035737 A1 WO 2013035737A1
Authority
WO
WIPO (PCT)
Prior art keywords
bifidobacterium
ability
mucin
bacteria
adhere
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/072605
Other languages
English (en)
Japanese (ja)
Inventor
早川　弘子
曽根　春恵
飯野　透
石川　文保
敏彦 高田
敏 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Priority to JP2013532622A priority Critical patent/JP5980785B2/ja
Publication of WO2013035737A1 publication Critical patent/WO2013035737A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the present invention relates to a novel bacterium belonging to the genus Bifidobacterium that can remain in the intestinal tract and can grow in the intestinal tract, and its use.
  • Bifidobacterium is a major bacterium in the intestinal flora of humans and has beneficial effects on human health such as bowel regulation such as constipation and diarrhea improvement, serum cholesterol elevation suppression, and immunostimulation. Many products are sold in the form of various fermented foods and beverages, viable bacteria preparations, and the like.
  • Bifidobacterium is considered to exert the above-mentioned effects mainly in the state of viable bacteria, increasing the survival of Bifidobacterium in fermented foods and beverages and viable preparations, and increasing the number of living organisms.
  • Various devices for ingesting bacteria have been made.
  • the above effect may not be fully exerted by simply passing the Bifidobacterium bacterium through the intestinal tract, and the Bifidobacterium bacterium remains in the intestine and proliferates in the intestine. It is considered important to do.
  • Lactobacillus GG ATCC 53103
  • Lactobacillus paracasei KW3110 etc.
  • lactic acid bacteria bacteria having the ability to adhere to the intestinal tract
  • Patent Documents 1 and 2 Bifidobacterium bifidum WB1003
  • Bifidobacterium genus bacteria is reported as Bifidobacterium genus bacteria.
  • an object of the present invention is to provide a Bifidobacterium bacterium that can not only stay in the intestine but also grow in the intestine.
  • the present inventors have used a number of Bifidobacterium bacteria as an index of having an ability to assimilate mucin, which is a main component of the intestinal mucosa, in addition to the ability to adhere to intestinal cells.
  • the present inventors have found a novel Bifidobacterium genus that has an ability to adhere to intestinal cells and an ability to utilize mucin and can not only stay in the intestinal tract but also grow in the intestinal tract, thereby completing the present invention.
  • the present invention provides a Bifidobacterium bacterium characterized by having the ability to adhere to intestinal cells and the ability to assimilate mucin.
  • this invention provides the food / beverage products characterized by containing the said Bifidobacterium genus bacteria, especially fermented milk food / beverage products. Furthermore, the present invention relates to a Bifidobacterium genus that remains in the intestinal tract and is capable of growing in the intestinal tract, wherein the Bifidobacterium genus bacterium is selected using as an index the ability to adhere to intestinal cells and the ability to utilize mucin. The screening method is provided.
  • the Bifidobacterium of the present invention has the ability to adhere to intestinal cells and the ability to assimilate mucin, it can stay in the intestine and can grow in the intestine, and the Bifidobacterium in the intestine Can exert the physiological effect of the bacterium effectively and continuously. Moreover, it can utilize suitably for manufacture of the food / beverage products which have these physiological effects, especially fermented milk food / beverage products.
  • B. Ability to adhere to HT-29 cells It is a figure which shows the adhesion image of bifidum YIT 11926 (in the figure, the part which has developed the yellow fluorescence shows YIT 11926 adhered to HT-29 cells).
  • B. Ability to adhere to HT-29 cells It is a figure which shows the adhesion image of bifidum YIT 11939 (In the figure, the part which has developed the yellow fluorescence shows YIT 11939 adhered to HT-29 cells).
  • the Bifidobacterium of the present invention has the ability to adhere to intestinal cells and the ability to assimilate mucin, and can remain in the intestine by having the ability to adhere to intestinal cells and has the ability to assimilate mucin Can grow in the intestine.
  • “having the ability to adhere to intestinal cells” means having the ability to adhere to intestinal cells to the extent that the target Bifidobacterium genus bacteria can remain in the intestinal tract. There are no restrictions on the type of adhesion or the like. Specifically, when a sufficient amount (50 or more per HT-29 cell) of Bifidobacterium is allowed to act on HT-29 cells, which are human colon cancer-derived cells, for 2 hours. -Refers to the attachment of one or more Bifidobacterium per 29 cells. Preferably two or more bacteria adhere per HT-29 cell, more preferably three or more bacteria adhere, and more preferably 3-10 bacteria adhere. The larger the number of bacteria that adhere, the more efficiently it can stay in the intestinal tract, and therefore it can be suitably used as the Bifidobacterium bacterium of the present invention.
  • “having mucin assimilation ability” means turbidity (Klett value, Klett-Summerson colorimetric) when the target Bifidobacterium bacterium is cultured in a medium containing only mucin as a sugar source for 48 hours. Total, No. 66 filter) is 50 or more.
  • the kret value is preferably 75 or more, more preferably 100 or more, and further preferably 100 to 200. The higher the Klett value, the higher the ability to grow in the intestinal tract, and therefore it can be suitably used as the Bifidobacterium of the present invention.
  • the culture medium used for the mucin utilization test may be a medium in which mucin is added to a medium excluding the sugar source, and the composition of the medium excluding the sugar source is Rogosa medium, M-ILS medium, PY.
  • the composition can be a medium, a GAM medium, a TOS propionic acid medium, or the like.
  • the mucin to be added is preferably human intestinal mucin, but can be substituted with porcine stomach mucin.
  • the amount of mucin added is preferably 0.1 to 10% by mass in the medium, more preferably 0.5 to 5% by mass, and still more preferably 0.5 to 2% by mass.
  • Bifidobacterium genus subject to the present invention is not particularly limited.
  • Bifidobacterium breve Bifidobacterium breve
  • Bifidobacterium longum B. longum
  • Bifidobacterium bifidum Bifidobacterium Animarisu (B.animalis)
  • Bifidobacterium Zuisu B.suis
  • Bifidobacterium infantis B.infantis
  • Bifidobacterium shoe Doka Tenu error Tam (B.pseudocatenulat m), Bifidobacterium lactis (B.lactis), Bifidobacterium Gurobosamu (B.globosum), Bifidobacterium
  • Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium bifidum are highly safe species that have been used in dairy products for a long time, and various physiological effects have been reported.
  • Bifidobacterium bifidum is preferred.
  • Bifidobacterium bacteria having 1 or more adherent bacteria per HT-29 cell and a kret value of 50 or more were selected.
  • the number of adherent cells per HT-29 cell is 0.1 to 0.6, and the kret value is about 10 to 40.
  • the Bifidobacterium of the present invention has the ability to adhere to intestinal cells and the ability to assimilate mucin, so that it remains in the intestine and can grow in the intestine, and the physiological effects of Bifidobacterium Can be effectively and continuously exhibited.
  • the Bifidobacterium of the present invention grows even in a bile acid-containing medium, has excellent bile acid resistance, and can reach the intestine in an orally alive state.
  • the new strains thus selected were designated as Bifidobacterium bifidum YIT 11926 (FERM BP-11504) and Bifidobacterium bifidum YIT 11939 (FERM BP-11505) on September 6, 2011. Deposited at the Patent Biological Depositary Center (1st, 1st East, 1st Street, 1st Street, Tsukuba City, Ibaraki Prefecture). These strains have the following mycological properties.
  • Bifidobacterium bifidum YIT 11926 The bacterium is isolated from healthy adults and has scientific properties of Gram-positive polymorphic gonococci, obligate anaerobes, and optimal growth temperature of 37 ° C.
  • the 16S rDNA base sequence obtained from YIT 11926 was searched from a database to identify the bacterial species.
  • the 16S rDNA base sequence of Bifidobacterium bifidum YIT 11926 showed 99.5% homology with Bifidobacterium bifidum DSM20456 (accession No. M38018) and was identified as Bifidobacterium bifidum.
  • Bifidobacterium bifidum YIT 11939 The bacterium is isolated from healthy adults and has scientific properties of Gram-positive polymorphic gonococci, obligate anaerobes, and optimal growth temperature of 37 ° C.
  • the 16S rDNA base sequence obtained from YIT 11939 was searched from a database to identify the bacterial species.
  • the 16S rDNA base sequence of Bifidobacterium bifidum YIT 11939 showed 99.6% homology with Bifidobacterium bifidum DSM20456 (accession No. M38018) and was identified as Bifidobacterium bifidum.
  • the utilization form of the bacterium belonging to the genus Bifidobacterium of the present invention is not particularly limited, and may be lyophilized, or may be used as a culture containing these bacteria.
  • the bacterium is preferably in a live state.
  • the Bifidobacterium of the present invention can be mixed with a solid or liquid non-toxic pharmaceutical carrier and used in the form of a conventional pharmaceutical preparation.
  • preparations include solid preparations such as tablets, granules, powders and capsules, liquid preparations such as solutions, suspensions and emulsions, and freeze-dried preparations. These preparations can be prepared by conventional means on the preparation.
  • non-toxic pharmaceutical carrier examples include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, albumin , Water, physiological saline and the like.
  • conventional additives such as stabilizers, wetting agents, emulsifiers, binders, isotonic agents, excipients and the like can be appropriately added as necessary.
  • the Bifidobacterium genus bacterium of the present invention can be used not only in the preparation as described above but also in food and drink. What is necessary is just to make it contain with a various nutrient component as it is, when mix
  • an additive that can be used as a food or drink is appropriately used, and a form suitable for food using conventional means, that is, a granular form , Granulated, tablets, capsules, pastes, etc., added to various foods such as processed meats such as ham and sausage, fishery processed foods such as kamaboko and chikuwa, bread, confectionery, butter and milk powder Or may be used by adding to beverages such as water, fruit juice, milk, soft drinks and tea drinks.
  • the food and drink includes animal feed.
  • the Bifidobacterium genus bacterium of the present invention can effectively and continuously exert physiological effects such as an intestinal regulating action possessed by the Bifidobacterium bacterium.
  • physiological effects such as an intestinal regulating action possessed by the Bifidobacterium bacterium.
  • it stays in the intestinal tract and can grow in the intestinal tract, even if it does not continuously ingest Bifidobacterium spp., For example, when the intake interval is opened, such as every other month, every other week, every other day Since the physiological effect can be expected even if the period is short, the economic merit is also great.
  • fermented milk food and drink fermented soy milk, fermented fruit juice, fermented vegetable juice and the like containing the Bifidobacterium bacterium of the present invention in the state of viable bacteria are preferably used, particularly fermented.
  • Use of dairy foods and drinks is preferred.
  • Fermented milk foods and drinks may be produced in accordance with conventional methods.
  • the sterilized milk medium is inoculated and cultured with the Bifidobacterium of the present invention alone or simultaneously with other microorganisms, This is homogenized to obtain a fermented milk base.
  • a separately prepared syrup solution may be added and mixed, homogenized with a homogenizer or the like, and then a flavor may be added to finish the final product.
  • the fermented milk food / beverage product thus obtained can be made into a product in any form such as a plain type, a soft type, a fruit flavor type, a solid form, and a liquid form that does not contain a syrup (sweetener).
  • Such fermented milk foods and drinks can contain optional ingredients such as sweeteners such as syrup, emulsifiers, thickening (stabilizing) agents, and various vitamins.
  • Syrup includes glucose, sucrose, fructose, fructose glucose liquid sugar, glucose fructose liquid sugar, palatinose, trehalose, lactose, xylose, maltose, honey, molasses and other sugars, sorbitol, xylitol, erythritol, lactitol, palatinit, reduced starch syrup
  • High-sweetness sweeteners such as sugar alcohols such as reduced maltose starch syrup, aspartame, thaumatin, sucralose, acesulfame K, stevia.
  • Fermented milk foods and drinks include sucrose fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, lecithin and other emulsifiers, agar, gelatin, carrageenan, guar gum, xanthan gum, pectin, locust bean gum, gellan gum, A thickening (stabilizing) agent such as carboxymethyl cellulose, soybean polysaccharide, propylene glycol alginate and the like may be blended.
  • vitamins such as vitamin A, vitamin B, vitamin C and vitamin E, minerals such as calcium, magnesium, zinc, iron and manganese, citric acid, lactic acid, acetic acid, malic acid, tartaric acid, glucone Acid flavors such as acids, milk fat such as cream, butter, sour cream, yogurt, berry, orange, quince, perilla, citrus, apple, mint, grape, apricot, pair, custard cream Flavors such as peach, melon, banana, tropical, herbal, tea, and coffee, herb extract, brown sugar extract, and the like can also be blended.
  • microorganisms other than the Bifidobacterium of the present invention can be used in combination.
  • examples of such microorganisms include Bifidobacterium breve ( Bifidobacterium breve ), Bifidobacterium longum ( B. longum ), Bifidobacterium bifidum ( B. bifidum ), Bifidobacterium animalis ( B. animalis ), Bifidobacterium zuis ( B. suis ), Bifidobacterium infantis ( B. infantis ), Bifidobacterium adrecentis ( B.
  • Bifidobacterium catenuratam B.catenulatum
  • Bifidobacterium shoe Doka Tenu error Tam B.pseudocatenulatum
  • Bifidobacterium lactis B.l CTIS
  • Bifidobacterium Gurobosamu B.globosum
  • Bifidobacterium angular Tam B.angulatum
  • bifidobacteria of the present invention such as Bifidobacterium Dentiumu (B.dentium) Bifidobacteria other than bacteria, Lactobacillus casei , Lactobacillus acidophilus, L. plantarum, L. plantarum, L.
  • Lactobacillus brevis L. brevis
  • Lactobacillus Ramunozasu L.rhamnosus
  • Lactobacillus kefir L.kefir
  • Lactobacillus paracasei L.paracasei
  • Lactobacillus crispatus L.crispatus
  • Lactobacillus Zeae L.zeae
  • Lactobacillus helveticus L.helveticus
  • Lactobacillus salivarius L.salivalius
  • Lactobacillus gasseri L.gasseri
  • Lactobacillus fermentum L.fermentum
  • Lactobacillus reuteri L.
  • Lactobacillus delbrukki Subspecies Bulgaricus ( L. delbrueckii subsp. Bulgaricus ), Lactobacillus delbrukki subspecies. Deruburukkyi (L.delbrueckii subsp. Delbrueckii), Lactobacillus John Sony (L.johnsonii) Lactobacillus bacteria such as, Streptococcus thermophilus (Streptococcus thermophilus) Streptococcus bacteria such as, Lactococcus lactis subsp. Lactococcus lactis subsp. Lactis , Lactococcus lactis subspecies.
  • Cremoris Lactococcus bacteria such as, Enterococcus faecalis (Enterococcus faecalis), Enterococcus faecium (E.faecium) Enterococcus bacteria such as Bacillus subtilis (Bacillus subtilis) bacteria belonging to the genus Bacillus such as, Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Torulaspora delbruecki ( Tollaspora delbrueckii ), Candida kefir ( Candida kefyr ), etc.
  • the preferred dose is 10 5 cfu to 10 13 cfu per day as the number of viable bacteria, especially 10 8 cfu. ⁇ 10 12 cfu is preferred.
  • the physiological effect can be expected even when the administration interval is opened, such as every other month, every other week, every other day, or even in a short intake period, instead of continuous administration.
  • Bifidobacterium bacteria that remain in the intestinal tract and can grow in the intestinal tract. That is, by selecting Bifidobacterium bacteria using the above-mentioned criteria for adhesion to intestinal cells and the criteria for mucin utilization, the ability to adhere to intestinal cells is selected. In addition, a Bifidobacterium genus having mucin utilization ability, staying in the intestinal tract, and capable of growing in the intestinal tract can be obtained.
  • the above-mentioned criteria also apply to Bifidobacterium bacteria that have only the ability to adhere to intestinal cells and remain in the intestinal tract, and Bifidobacterium bacteria that have only mucin-assimilating ability and can grow in the intestinal tract. Can be used. In other words, if a strain having an ability to adhere to intestinal cells that exceeds the reference value and a mucin utilization ability that is less than the reference value is selected, a Bifidobacterium bacterium that has only the ability to adhere to intestinal cells and remains in the intestinal tract is obtained.
  • Bifidobacterium genus that has only mucin-assimilating ability and can grow in the intestinal tract if a strain having a mucin-assimilating ability greater than the reference value and an ability to adhere to intestinal cells is less than the reference value is selected. Bacteria can be obtained.
  • bacteria other than Bifidobacterium it is possible to determine whether or not the bacteria have the ability to adhere to intestinal cells and the ability to utilize mucin.
  • Example 1 Selection of Bifidobacterium bacteria having adhesive ability and mucin assimilation into intestinal cells (1) mucin Shikano B. adolescentis , B. et al . bifidum, B. breve , B.B. catenulatum, B. longum , B.B. pseudocateulatum , B.I. angulatum , B. et al . animalis, B. infantis, B. globosum, B. lactis , B. et al . dentium, L. Using the 13 species of test strains of rhamnosus.
  • Bifidobacteria were inoculated with 1% of a test bacterial solution cryopreserved in a GAM anaerobic liquid medium supplemented with 0.7% glucose and pre-cultured for 24 hours.
  • Lactobacillus L. rhamnosus
  • MRS liquid medium 1% of a test bacterial solution cryopreserved in MRS liquid medium and pre-cultured for 24 hours.
  • Inoculate 1% of the precultured culture medium (mucin addition amount is 1%) on the medium in which the lactose of M-ILS is replaced with mucin (Wako, manufactured by porcine stomach) (the initial bacterial count is 10 7 / ml / medium)
  • the kret value was measured.
  • culture was performed for 48 hours in an M-ILS medium to which no carbohydrate was added, and the kret value was measured.
  • HT-29 was cultured on a glass slide with a chamber until it became confluent, 400 ⁇ l of a cell suspension suspended in RPMI-1640 supplemented with 10% FBS was added (the number of test strains per HT-29 cell was 300). Will be). After 2 hours of incubation at 37 ° C. and 5% CO 2 , the plate was washed twice with 10% FBS-supplemented RPMI-1640 medium and once with PBS to remove non-adherent bacteria and 2% PFA was added at 4 ° C. Fixed overnight.
  • the bifidobacteria specific probe Bif153 labeled with the fluorescent dye Cy5 for Bifidobacteria (Intestinal Bacteriology Journal 18: 141-146, 2004), and for the lactic acid bacteria with the fluorescent dye Cy5 Hybridization was performed using a labeled lactic acid bacteria-specific probe Lab158 (Microb. Ecol. Health Dis. 11: 3-12, 1999), which was sealed with a mounting medium to which a DAPI stain was added, and a fluorescent image was obtained using a fluorescent microscope system.
  • the number of adherent bacteria of each test strain per HT-29 cell was quantified using image processing software.
  • FIGS. 1 and 2 show images of strains having the ability to adhere to HT-29 cells
  • FIGS. 3 and 4 show images of strains that have no ability to adhere.
  • YIT 11926 and YIT 11939 YIT 10155, 31-2, YIT 4044, and YIT 4018 possessed the ability to adhere to intestinal cells, but these four strains all had low ability to assimilate mucin.
  • the ability to assimilate mucin and the ability to adhere to intestinal cells the variation among strains was very large even in the same species, and no particular tendency of the same species was observed.
  • L. Rhamnosus GG is known as a lactic acid bacterium having the ability to adhere to the intestinal tract (Patent Document 1), but this test system also showed the same ability to adhere to intestinal cells as YIT 11939.
  • bile acid resistance was examined for some bifidobacteria. Specifically, 30 ⁇ l of the bacterial solution cultured anaerobically to the stationary phase in the GAM liquid medium was inoculated into 3 ml of the GAM liquid medium supplemented with 0.2% bile acid and cultured anaerobically at 37 ° C. After the time, microbial turbidity (Cret value) was measured with a Klett-Summerson colorimeter (No. 66 filter).
  • a high Klett value indicating growth in a bile acid-containing medium indicates a high survival rate and growth rate in the gastrointestinal tract, and a Bifidobacterium having a Klett value of 100 or more in the bile acid-containing medium. Can reach the intestines with a large number of bacteria alive.
  • Klett value of YIT 11926 is 125, YIT 11939 is 135, B. YIT 4039, which is a type strain of bifidum , hardly grew on the BAM-added GAM medium.
  • General bifidobacteria proliferating in a bile acid-containing medium has a Klett value of about 0 to several tens. Therefore, it was revealed that YIT 11926 and YIT 11939 have high bile acid resistance. .
  • Example 2 Manufacture of fermented milk foods and beverages 15% skimmed milk was sterilized by adding 3% glucose, inoculated with 1% Bifidobacterium bifidum YIT 11939, cultured at 37 ° C for 24 hours, and yogurt base 210 g was obtained. On the other hand, 97 g of sugar and 0.2 g of emulsified iron were dissolved in water and sterilized with a total amount of 790 g to obtain a syrup. The yogurt base and syrup obtained as described above were mixed, 1 g of flavor was added, and then homogenized at 15 MPa and filled in a container to obtain a fermented milk beverage. The obtained fermented milk beverage had good appearance and flavor and good storage stability.
  • Example 3 Manufacture of fermented milk foods and drinks 124g whole milk powder was dissolved in 506g water and sterilized at 135 ° C for 3 seconds, then Bifidobacterium breve 0.5%, Bifidobacterium bifidum YIT 11926 1% and Lactobacillus acidophilus 0.001% were inoculated, cultured at 37 ° C. to pH 5.3, and homogenized at 15 MPa to obtain 630 g of a bacterial solution.
  • Example 4 Manufacture of tablets Various ingredients were mixed according to the following formulation, granulated, dried and sized, and then tableted to produce tablets. (Prescription) (mg) Dried product of bacterial cells of the present invention 1) 20 Microcrystalline cellulose 100 Lactose 80 Magnesium stearate 0.5 Methylcellulose 12 1) A living cell of Bifidobacterium bifidum YIT 11926 was produced by lyophilization.
  • Example 5 Manufacture of soft drink According to the following prescription, each component was blended according to a conventional method and homogenized to obtain a soft drink. The obtained soft drink was filled in a brown bottle, sealed with an aluminum cap, and heat-treated. The resulting soft drink had good appearance and flavor and good storage stability.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une bactérie appartenant au genre Bifidobacterium, qui peut rester dans le tractus intestinal et peut proliférer dans le tractus intestinal. L'invention concerne une bactérie appartenant au genre Bifidobacterium, caractérisée en ce qu'elle est apte à adhérer à des bactéries de l'intestin et qu'elle est apte à utiliser la mucine.
PCT/JP2012/072605 2011-09-08 2012-09-05 Nouveau bifidobacterium et son utilisation Ceased WO2013035737A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013532622A JP5980785B2 (ja) 2011-09-08 2012-09-05 新規ビフィズス菌及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011195684 2011-09-08
JP2011-195684 2011-09-08

Publications (1)

Publication Number Publication Date
WO2013035737A1 true WO2013035737A1 (fr) 2013-03-14

Family

ID=47832182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/072605 Ceased WO2013035737A1 (fr) 2011-09-08 2012-09-05 Nouveau bifidobacterium et son utilisation

Country Status (2)

Country Link
JP (1) JP5980785B2 (fr)
WO (1) WO2013035737A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087661A (zh) * 2016-11-29 2019-08-02 森永乳业株式会社 苷元产生促进剂
JP2022086175A (ja) * 2020-11-30 2022-06-09 株式会社ヤクルト本社 ヒト腸内に長期定着する微生物のスクリーニング方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009189374A (ja) * 2003-06-30 2009-08-27 Clasado Inc 新規のガラクトオリゴサッカライド組成物およびその調製法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009189374A (ja) * 2003-06-30 2009-08-27 Clasado Inc 新規のガラクトオリゴサッカライド組成物およびその調製法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIESEBEKE, R,T. ET AL.: "Microbial functionality in th human gastrointestinal tract", MICROBES ENVIRON., vol. 19, no. 4, 2004, pages 276 - 280 *
RUAS-MADIEDO,P. ET AL.: "Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota", APPL.ENV. MICROBIOL., vol. 74, no. 6, 2008, pages 1936 - 1940 *
TURRONI,F. ET AL.: "Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging", PROC.NATL.ACAD.SCI.USA, vol. 107, no. 45, 2010, pages 19514 - 19519 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087661A (zh) * 2016-11-29 2019-08-02 森永乳业株式会社 苷元产生促进剂
JPWO2018100776A1 (ja) * 2016-11-29 2019-10-17 森永乳業株式会社 アグリコン産生促進剤
EP3549593A4 (fr) * 2016-11-29 2020-08-12 Morinaga Milk Industry Co., Ltd. Promoteur de la production d'aglycone
JP2022086175A (ja) * 2020-11-30 2022-06-09 株式会社ヤクルト本社 ヒト腸内に長期定着する微生物のスクリーニング方法
JP7570216B2 (ja) 2020-11-30 2024-10-21 株式会社ヤクルト本社 ヒト腸内に長期定着する微生物のスクリーニング方法

Also Published As

Publication number Publication date
JPWO2013035737A1 (ja) 2015-03-23
JP5980785B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5518178B2 (ja) ラクトバチルス・プランタラムに属する新規乳酸菌およびその利用
TWI495722B (zh) 新穎雙叉桿菌屬細菌、含有其之飲食品、用於檢測或定量其之dna片段及引子之用途、與其檢測或定量方法
CN101257910B (zh) 胆固醇吸收抑制剂
US11331353B2 (en) Sleep quality improver
JP6088821B2 (ja) 乳酸菌および／またはビフィズス菌の生残性向上剤
KR102146429B1 (ko) 비피도박테리움 아니말리스 아종 아니말리스 균주
EP1972208A1 (fr) Composition pour améliorer la flore microbienne intestinale
WO2021256476A1 (fr) Procédé pour améliorer la résistance de bactéries lactiques à des sucs gastriques ou à la bile
Vitheejongjaroen et al. Antioxidant activity of Bifidobacterium animalis MSMC83 and its application in set-style probiotic yoghurt
Tanaka et al. Short-and long-term dynamics in the intestinal microbiota following ingestion of Bifidobacterium animalis subsp. lactis GCL2505
JPWO2005092122A1 (ja) ユッカ抽出物、キラヤ抽出物及び乳酸菌からなる組成物及び同組成物を含有する飲食品
EP3328208B1 (fr) Procédés de préparation de produits fermentés comprenant des bifidobactéries
JP2022188291A (ja) 乳酸菌用培地
JP5980785B2 (ja) 新規ビフィズス菌及びその利用
WO2017047776A1 (fr) Inhibiteur d'élévation de la concentration de tryptophane sanguin
WO2025005237A1 (fr) Composition pour lutter contre des bactéries appartenant au genre fusobacterium dans la flore intestinale, et son utilisation
HK1181420B (en) Lactobacillus classified as lactobacillus plantarum and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830836

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013532622

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12830836

Country of ref document: EP

Kind code of ref document: A1